Lecanemab’s list price is $26,500 per year, and the ICER said its health-benefit price benchmark is between $8,900 and $21,500 per year. Of the 15 panelists part of the decision, all said the current price shows a “low” long-term value, according to a report released April 17.
The FDA approved the drug in early January, but CMS refused to adjust its Aduhelm-era coverage plan, setting a more strained market for the treatment.
In a phase 3 trial, the anti-amyloid drug slowed cognitive decline by 27 percent in a global study of 1,795 people with mild cognitive impairment or mild Alzheimer’s disease. However, the ICER said the drug costs 19 percent to 66 percent higher than its benefit.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.